Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated?
Montalescot
Gilles
G
Silvain
Johanne
J
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000503:physiopathology; D002908:Chronic Disease; D006470:Hemorrhage / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology*; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D012307:Risk Factors; D000077486:Ticagrelor
C548576:P2RY12 protein, human; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000077486:Ticagrelor; D000241:Adenosine